Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Want to see JP:4512 full AI Analyst Report?
Top Page
Wakamoto Pharmaceutical Co., Ltd.
(4512)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥298.00
▲(4.20% Upside)
Action:Reiterated
Date:05/19/26
The score is driven primarily by solid balance-sheet quality and improved recent profitability, but it is held back by persistently negative operating/free cash flow and a weak technical trend (trading below major moving averages). A high P/E and modest dividend yield further limit the valuation support.
Positive Factors
Balance sheet strength
Extremely low leverage and a sizeable equity base provide durable financial flexibility, enabling the company to absorb shocks, fund R&D or working-capital needs without needing external debt. This conservatism supports long-term solvency and strategic optionality.
Negative Factors
Weak cash generation
Sustained negative operating and free cash flow across multiple years undermines earnings quality and raises reliance on reserves despite low debt. Persistent cash outflows constrain capital spending, R&D funding, and any meaningful shareholder returns without altering operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low leverage and a sizeable equity base provide durable financial flexibility, enabling the company to absorb shocks, fund R&D or working-capital needs without needing external debt. This conservatism supports long-term solvency and strategic optionality.
Read all positive factors
Wakamoto Pharmaceutical Co., Ltd. (4512) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.68B
Dividend Yield1.06%
Average Volume (3M)65.94K
Price to Earnings (P/E)42.6
Beta (1Y)0.39
Revenue Growth27.18%
EPS Growth252.59%
CountryJP
Employees403
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-5.12
Shares Outstanding34,838,326
10 Day Avg. Volume55,010
30 Day Avg. Volume65,936
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.01
Price to Sales (P/S)1.23
P/FCF Ratio-11.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provid...
How the Company Makes Money
Wakamoto Pharmaceutical primarily makes money by selling its pharmaceutical and health-related products in Japan. Its revenue model is centered on (1) product sales through distribution channels such as pharmacies, drugstores, and other retail/who...
Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
84
Very Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.98B | 9.91B | 7.79B | 7.74B | 8.66B | 8.38B |
| Gross Profit | 3.75B | 4.73B | 3.62B | 3.54B | 4.11B | 4.36B |
| EBITDA | 397.01M | 698.48M | 438.68M | 504.84M | 575.81M | 755.52M |
| Net Income | -177.67M | 227.22M | 64.44M | 108.96M | 138.26M | 238.54M |
Balance Sheet | ||||||
| Total Assets | 15.25B | 16.50B | 15.00B | 15.42B | 15.71B | 14.95B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 2.01B | 2.95B | 3.66B | 3.88B | 3.23B |
| Total Debt | 100.00M | 400.00M | 100.00M | 130.73M | 529.00K | 2.65M |
| Total Liabilities | 3.55B | 4.49B | 3.39B | 3.39B | 3.80B | 3.47B |
| Stockholders Equity | 11.70B | 12.01B | 11.61B | 12.03B | 11.91B | 11.48B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.05B | -1.04B | -663.02M | 420.76M | -28.97M |
| Operating Cash Flow | 0.00 | -486.91M | -592.45M | -107.34M | 631.92M | 339.17M |
| Investing Cash Flow | 0.00 | -657.56M | -13.50M | -2.35M | 17.13M | 50.57M |
| Financing Cash Flow | 0.00 | 195.88M | -103.94M | -104.99M | -1.61M | -1.62M |
Wakamoto Pharmaceutical Co., Ltd. Technical Analysis
Negative
286.00
Price Trends
335.45
Negative
325.04
Negative
307.63
Negative
Market Momentum
-18.51
Positive
27.33
Positive
12.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 286 is below the 20-day moving average (MA) of 316.45, below the 50-day MA of 335.45, and below the 200-day MA of 307.63, indicating a bearish trend. The MACD of -18.51 indicates Positive momentum. The RSI at 27.33 is Positive, neither overbought nor oversold. The STOCH value of 12.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.
Wakamoto Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥12.82B | 24.00 | ― | ― | 1.62% | -25.43% | |
63 Neutral | ¥8.81B | 14.09 | ― | 2.55% | -0.61% | 14.60% | |
63 Neutral | ¥34.68B | 11.93 | ― | 2.75% | 3.94% | 40.63% | |
53 Neutral | ¥9.68B | 42.62 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥18.74B | -11.15 | ― | 3.65% | 12.41% | -161.06% | |
52 Neutral | ¥17.88B | 8.65 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
279.00
-19.48
-6.53%
JP:2929
Pharma Foods International Co., Ltd.
647.00
-296.04
-31.39%
JP:4524
Morishita Jintan Co., Ltd.
2,160.00
104.95
5.11%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,038.00
-36.46
-1.76%
JP:4574
Taiko Pharmaceutical Co., Ltd.
256.00
2.00
0.79%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,202.00
252.88
26.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.